


Listing of Claims:

1-22. (cancelled)

23. (allowable) A compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, or 2;

q represents an integer being 0, 1, or 2;

X represents O, S, NR³ or a direct bond;

R¹ represents hydrogen, hydroxy, halo, amino, C₁₋₆alkyl, C₁₋₆alkyloxy or mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkylamino; in particular, hydrogen, methyl and hydroxy;

R² represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹;

each R⁴ independently represents C₁₋₆alkyl, halo, polyhaloC₁₋₆alkyl or C₁₋₆alkyloxy;

each R⁵ independently represents C₁₋₆alkyl, halo or C₁₋₆alkyloxy;

each R⁶ independently represents C₁₋₆alkylsulfonyl, aminosulfonyl or phenylC₁₋₄alkylsulfonyl;

each R⁷ and each R⁸ are independently selected from hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, dihydroxyC₁₋₄alkyl, aryl, arylC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, mono- or di(C₁₋₄alkyl)aminoC₁₋₄alkyl, arylaminocarbonyl, arylaminothiocarbonyl, C₃₋₇cycloalkyl, pyridinylC₁₋₄alkyl, Het³ and R⁶;

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkylcarbonyloxyC₁₋₄alkylcarbonyl, hydroxyC₁₋₄alkylcarbonyl, C₁₋₄alkyloxycarbonylcarbonyl, Het³aminothiocarbonyl and R⁶;

each R^{11} independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C_{1-4} alkyloxy, carboxyl, C_{1-4} alkyloxycarbonyl, trihalo C_{1-4} alkylsulfonyloxy, R^6 , NR^7R^8 , $C(=O)NR^7R^8$, aryl, aryloxy, arylcarbonyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, phthalimide-2-yl, Het^3 and $C(=O)Het^3$;

R^{12} and R^{13} are each independently selected from hydrogen and C_{1-4} alkyl;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy, polyhalo C_{1-4} alkyl, NR^9R^{10} , R^6 , phenyl, Het^3 and C_{1-4} alkyl substituted with NR^9R^{10} ;

Het^1 represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1*H*-pyrazolo-[3,4-*d*]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-*b*]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2 , R^{11} and C_{1-4} alkyl optionally substituted with Het^2 or R^{11} ;

Het^2 represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with C_{1-4} alkyl;

Het^3 represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from C_{1-4} alkyl, C_{1-4} alkyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, phenyl C_{1-4} alkyl, piperidinyl, $NR^{12}R^{13}$ and C_{1-4} alkyl substituted with $NR^{12}R^{13}$.

24. (allowable) A compound according to claim 23 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

25. (allowable) A compound according to claim 24 wherein *q* is 1 or 2 and one R^4 substituent is in the 4 position; and *p* is 1 or 2 and the one or two R^5 substituents are in the ortho position relative to the central carbon atom.

26. (allowable) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 23.

27. (allowable) A process for preparing a composition as claimed in claim 26, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 23.

28. (cancelled)

29. (allowable) A method for treating one or more of bronchial asthma, atopic dermatitis, allergic-rhinitis or allergic conjunctivitis in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of Claim 23.

30. (cancelled).

31. (allowable) A method for inhibiting IL-5 production in a warm-blooded animal, comprising administering to the warm-blooded animal an effective amount of a compound of claim 23.